An observational study in Glioma, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by Huashan Hospital · Observational
Glioblastoma (GBM) is the most malignant primary intracranial tumor with a median survival of about 18 months, and new therapies are urgently needed. Tumor vaccines has been shown to improve survival of GBM, but not all patients can benefit from vaccine treatment and biomarkers are urgently needed. Deletion of mismatch repair (MMR) protein and microsatellite instability (MSI) state are important features in the biological evolution of GBM, and may be used as markers for tumor vaccine. Therefore, this project will collect samples from GBM patients before and after vaccine treatment respectively, and evaluate the role of MMR/MSI gene phenotype in predicting vaccine efficacy and the potential molecular mechanism. Moreover, MMR/MSI phenotypes will be assessed by deep-learning and radiomics using images to establish noninvasive markers for vaccine.
1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.
This study's planned enrollment of 360 is above the median of 88 across 238 observational studies indexed under Glioma.
Browse Glioma studies →Huashan Hospital is the lead sponsor of 239 studies on the registry; 102 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients undergoing glioma surgery at Huashan Hospital
The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled
Exclusion Criteria:
Patients who meet any of the following criteria will not be included in this study:
surgery
surgery and DC vaccine
Biological: DC vaccine
DC vaccine produced by the Team
Transcriptomics
The issues collected will be used for transcriptome sequencing to measure gene expression level.
Time frame: 36 months
Immunomics
The issues collected will be used for TCR/BCR sequencing to measure clonality of lymphocytes
Time frame: 36 months
Proteomics
The issues collected will be used for TCR/BCR sequencing to measure gene expression level in protein
Time frame: 36 months
Radiomics
The features from images will be extracted using algorithm of Deep-learning or Radiomics
Time frame: 36 months
IHC analysis
Different expression level of proteins (CD3,CD8,B7-H4, MMR proteins) in Gliomas with different grades and molecular subgroups (300 cases) will be measured using immunohistochemical.
Time frame: 36 months
Genomics
The issues collected will be used for whole genome sequencing or whole exome sequencing to measure gene mutations.
Time frame: 36 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huashan Hospital